DKK1 and Miyoshi myopathy: Moreover, an early phase I clinical trial, expected to start in October 2022, will study the safety and efficacy of DKK1 as MM-TAA in DC-based immunotherapy for MGUS, SMM and active MM patients (clinicaltrials.gov identifier: NCT03591614).